Utility of immunohistochemical analysis for cyclo-oxygenase 2 in the differential diagnosis of osteoblastoma and osteosarcoma

Journal of Clinical Pathology

Volumn 60, Issue 4, 2007, Pages 410-414

  Hosono, Ako ^b   Yamaguchi, Umio ^b   Makimoto, Atsushi ^b   Endo, Makoto ^b   Watanabe, Atsuko ^b   Shimoda, Tadakazu ^b   Kaya, Mitsunori ^a   Matsumura, Tadaki ^a   Sonobe, Hiroshi ^c   Kusumi, Tomomi ^d   Yamaguchi, Takehiko ^a   Hasegawa, Tadashi ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION FUKUYAMA MEDICAL CENTER   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; IMMUNOHISTOCHEMISTRY; MALE; OSTEOBLAST; OSTEOBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CYCLOOXYGENASE 2; DIAGNOSIS, DIFFERENTIAL; ENZYME TESTS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OSTEOBLASTOMA; OSTEOSARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 34247148024     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.038828     Document Type: Article

References (28)

1. Cheung FM, Wu WC, Lam CK, et al. Diagnostic criteria for pseudomalignant osteoblastoma. Histopathology 1997;31:196-200.
2. Mirra JM, Kendrick RA, Kendrick RE. Pseudomalignant osteoblastoma versus arrested osteosarcoma: a case report. Cancer 1976;37:2005- 14.
3. Dorfman HD, Weiss SW. Borderline osteoblastic tumors: problems in the differential diagnosis of aggressive osteoblastoma and low-grade osteosarcoma. Semin Diagn Pathol 1984;1:215-34.
4. Schajowicz F, Lemos C. Malignant osteoblastoma. J Bone Joint Surg Br 1976;58:202-11.
5. Mayer L. Malignant degeneration of so-called benign osteoblastoma. Bull Hosp Jt Dis 1967;28:4-13.
6. Seki T, Fukuda H, Ishii Y, et al. Malignant transformation of benign osteoblastoma. A case report. J Bone Joint Surg Am 1975;57:424-6.
7. Lucas DR, Unni KK, McLeod RA, et al. Osteoblastoma: clinicopathologic study of 306 cases. Hum Pathol 1994;25:117-34.
8. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-73.
9. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-86.
10. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
11. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
12. Kakiuchi Y, Tsuji S, Tsujii M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002;62:1567-72.
13. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.
14. Kawaguchi Y, Hasegawa T, Oka S, et al. Mechanism of intramedullary high intensity area on T2-weighted magnetic resonance imaging in osteoid osteoma: a possible role of COX-2 expression. Pathol Int 2001;51:933-7.
15. Kawaguchi Y, Sato C, Hasegawa T, et al. Intraarticular osteoid osteoma associated with synovitis: a possible role of cyclooxygenase-2 expression by osteoblasts in the nidus. Mod Pathol 2000;13:1086- 91.
16. Mungo DV, Zhang X, O'Keefe RJ, et al. COX-1 and COX-2 expression in osteoid osteomas. J Orthop Res 2002;20:159-62.
17. Dickens DS, Kozielski R, Khan J, et al. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 2002;5:356- 64.
18. Dickens DS, Kozielski R, Leavey PJ, et al. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol 2003;25:282-5.
19. Naruse T, Nishida Y, Hosono K, et al. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 2006;27:584-92.
20. Dorfman HD, Czerniak B, Kotz R, et al, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002:227-32.
21. Shinmura K, Ishida T, Goto T, et al. Expression of cyclooxygenase-2 in chondroblastoma: immunohistochemical analysis with special emphasis on local inflammatory reaction. Virchows Arch 2004;444:28-35.
22. Endo M, Matsumura T, Yamaguchi T, et al. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol 2006;37:471-6.
23. Sutton KM, Wright M, Fondren G, et al. Cyclooxygenase-2 expression in chondrosarcoma. Oncology 2004;66:275-80.
24. Bertoni F, Unni KK, McLeod RA, et al. Osteosarcoma resembling osteblastoma. Cancer 1985;55:416-26.
25. Williams CD, Mann M, Dubois RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogene 1999;18:7908-16.
26. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
27. Gasparini G, Longo R, Sarmiento R, et al. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
28. Agarwal B, Swaroop P, Protiva P, et al. Cox-2 is needed but not sufficient for apoptosis induced by COX-2 selective inhibitors in colon cancer cells. Apoptosis 2003;8:649-54.